Drugs / NNC0471-0119 H
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07068295 | Jul 2025 → Feb 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06809621 | Jan → Jul 2025 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0471-0119 H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06809621 ↗ |
| Known as | NNC0471-0119 | “This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump.” NCT07068295 ↗ |
| Modality | Protein / enzyme biologic | “new fast-acting insulin” NCT06809621 ↗ |
| Route | Subcutaneous | “NNC0471-0119 H will be administered subcutaneously.” NCT06809621 ↗ |